Clinical Trials on Respiratory Syncytial Virus Prevention

Total 11014 results

Janssen Vaccines & Prevention B.V.

Completed

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

Respiratory Syncytial Virus Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

Respiratory Syncytial Virus Prevention

United States
Janssen Pharmaceutical K.K.

Terminated

A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants

Respiratory Syncytial Virus Prevention

Japan
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

Respiratory Syncytial Virus Infection Prevention

Germany, Spain, Belgium, Sweden, United States
Janssen Vaccines & Prevention B.V.

Terminated

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Influenza, Human Prevention | Respiratory Syncytial Viruses Prevention

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Respiratory Syncytial Virus Immunization

United States, Australia, Puerto Rico
EuBiologics Co.,Ltd

Not yet recruiting

Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years (EuRSV)

Respiratory Syncytial Virus Infections | Respiratory Syncytial Virus (RSV)
Clover Biopharmaceuticals AUS Pty Ltd

Recruiting

First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults

Respiratory Syncytial Virus Infection

Australia
Vigonvita Life Sciences

Recruiting

A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV

Respiratory Syncytial Virus Infection

China
AbbVie (prior sponsor, Abbott)

Completed

Surveillance of Synagis in Korean Pediatric Patients

Respiratory Syncytial Virus Infection
Sanofi Pasteur, a Sanofi Company

Recruiting

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

Respiratory Syncytial Virus Infection

United States, Puerto Rico
Pfizer

Completed

A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.

Respiratory Syncytial Virus Infection

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (VAD00001)

Respiratory Syncytial Virus Infection

Honduras, United States, Chile
AbbVie (prior sponsor, Abbott)

Completed

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

Respiratory Syncytial Virus Infection

Japan
MedImmune LLC

Completed

MEDI-557 Adult Dosing (CD-1092)

Respiratory Syncytial Virus

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study) (BEAR)

Respiratory Syncytial Virus

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Respiratory Syncytial Virus

Canada, United Kingdom, Spain, Brazil, Sweden, Poland, Australia, Finland
ModernaTX, Inc.

Active, not recruiting

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

Respiratory Syncytial Virus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults

Respiratory Syncytial Virus

United States
Quidel Corporation

Completed

Sofia RSV FIA Field Study

Respiratory Syncytial Virus

United States
Shanghai Ark Biopharmaceutical Co., Ltd.
Ark Biosciences Pty Ltd.

Completed

Viral Inhibition in Children for Treatment of RSV (VICTOR)

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Australia, Hong Kong, Israel, Lebanon, Malaysia, Poland, Taiwan, Turkey
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older

Healthy Volunteers | Respiratory Syncytial Virus Infection

Australia
MedImmune LLC

Completed

Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

Respiratory Syncytial Virus Prophylaxis
National Institute of Allergy and Infectious Diseases...

Completed

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

Respiratory Syncytial Virus Infection | Antiviral Prophylaxis

United States
University of Rochester

Active, not recruiting

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

Respiratory Syncytial Virus (RSV)

United States
University of Oxford
Innovative Medicines Initiative; Respiratory syncytial virus consortium in...

Active, not recruiting

Understanding RSV: Severe Disease and the Long Term Consequences

Respiratory Syncytial Virus (RSV)

United Kingdom
Enanta Pharmaceuticals, Inc

Completed

Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

Respiratory Syncytial Virus (RSV)

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults

Respiratory Syncytial Virus (RSV)

Belgium
Novavax
PATH

Completed

RSV-F Vaccine Dose Ranging Study in Young Women

Respiratory Syncytial Virus (RSV)

United States
Pfizer

Completed

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease (MONET)

RESPIRATORY SYNCYTIAL VIRUS (RSV)

United States
Novavax

Completed

Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.

Respiratory Syncytial Virus (RSV)

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

Respiratory Syncytial Virus (RSV)

United States
AbbVie

Completed

Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis (SUNRISE)

Respiratory Syncytial Virus (RSV)
Hannover Medical School

Recruiting

Infection With Respiratory Syncytial Virus in Infants (IRIS)

Respiratory Syncytial Virus Infections | Respiratory Syncytial Virus (RSV) | Respiratory Syncytial Virus-bronchiolitis

Germany
Ablynx

Completed

ALX-0171 Safety Study in Adults With Hyperresponsive Airways

Respiratory Syncytial Virus Infection

Germany
Enanta Pharmaceuticals, Inc

Recruiting

A Study to Evaluate EDP 938 Regimens in Children With RSV (RSVPEDs)

Respiratory Syncytial Virus (RSV)

United States, Spain, Israel, Australia, Germany, Korea, Republic of, Taiwan, United Kingdom, Argentina, Brazil, New Zealand, Poland, Romania, South Africa, Mexico
Novavax

Completed

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

Respiratory Syncytial Virus (RSV)

United States
Novavax

Completed

Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults

Respiratory Syncytial Virus (RSV)

United States
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Healthy Volunteers | Respiratory Syncytial Virus Infection | Human Metapneumovirus

United States, Puerto Rico
ModernaTX, Inc.

Active, not recruiting

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Respiratory Syncytial Virus | Human Metapneumovirus

Spain, United Kingdom, Canada, Australia, United States, South Africa, Poland, Colombia, Argentina, Latvia, Panama
MedImmune LLC

Terminated

A Study to Evaluate the Efficacy of MEDI7510 in Older Adults

Respiratory Syncytial Virus

United States, Chile, South Africa, Canada, Estonia, Lithuania, Latvia
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines

Infections, Respiratory Syncytial Virus

Canada
ModernaTX, Inc.

Active, not recruiting

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

Respiratory Syncytial Virus

United States
GlaxoSmithKline

Completed

Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression

Infections, Respiratory Syncytial Virus

United States
ModernaTX, Inc.

Recruiting

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus

Canada, United Kingdom, Japan, United States, Chile, Denmark, Panama, South Africa
Merck Sharp & Dohme LLC

Completed

Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

Respiratory Syncytial Virus

United Kingdom
Dalhousie University
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Completed

A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine

Respiratory Syncytial Virus

Canada
ModernaTX, Inc.

Recruiting

A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults

Respiratory Syncytial Virus

Canada, United States, United Kingdom, Puerto Rico

3

Subscribe